NEW YORK, April 9, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
PerkinElmer, Inc. (NYSE: PKI), PAREXEL International Corporation
(NASDAQ: PRXL), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Response
Genetics, Inc. (NASDAQ: RGDX), and Foundation Medicine, Inc.
(NASDAQ: FMI). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
--
PerkinElmer, Inc. Analyst Notes
On April 4, 2014, PerkinElmer,
Inc. (PerkinElmer) announced that intends to release its Q1 2014
financial results on April 24, 2014,
after market close. On the same day, the Company has scheduled a
conference call at 5:00 p.m. ET to
discuss the results. PerkinElmer informed that its Chairman and
CEO, Robert F. Friel, and Senior
Vice President and CFO, Andy Wilson,
will host the conference call. The full analyst notes on
PerkinElmer, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04092014/PKI/report.pdf
--
PAREXEL International Corporation Analyst Notes
On April 1, 2014, PAREXEL
International Corporation (PAREXEL) announced that it intends to
release its financial results for Q3 FY 2014 on April 29, 2014, after the close of the stock
market. On the following day, April 30,
2014, the Company has scheduled a conference call and live
webcast at 10:00 a.m. EDT to discuss
the results. The full analyst notes on PAREXEL International
Corporation are available to download free of charge at:
http://www.AnalystsReview.com/04092014/PRXL/report.pdf
--
WuXi PharmaTech (Cayman) Inc. Analyst Notes
On April 1, 2014, WuXi PharmaTech
(Cayman) Inc. (WuXi) announced that WuXi Corporate Venture Fund has
made an investment in TruTag Technologies, Inc. (TruTag). The
Company informed that TruTag is a developer of the leading edible,
covert security platform to address the global product
counterfeiting challenge. In addition, the Companies announced that
they will explore collaborations to offer WuXi's global customers
the TruTag on-dose authentication solution to help prevent
counterfeiting and to enhance drug safety. "WuXi is pleased to
invest in this cutting-edge technology and to explore its further
development to enhance patient safety and protect our customers'
intellectual property," said Dr. Ge
Li, Chairman and CEO of WuXi. The full analyst notes on WuXi
PharmaTech (Cayman) Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/04092014/WX/report.pdf
--
Response Genetics, Inc. Analyst Notes
On April 3, 2014, Response
Genetics, Inc. (Response Genetics) announced that it has signed
agreements with six additional health plans across 10 states,
bringing the Company's total national contracted membership to more
than 174 million customers. Response Genetics stated that these new
agreements mark a further step forward in the Company's growing
managed care contracting program. Also, the Company said that with
these agreements, Response Genetics is now in-network with a total
of thirteen Blue Cross Blue Shield health plans, which brings the
total number of "Blues" subscribers with direct access to Response
Genetics to approximately 23 million. The full analyst notes on
Response Genetics, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/04092014/RGDX/report.pdf
--
Foundation Medicine, Inc. Analyst Notes
On April 3, 2014, Foundation
Medicine, Inc. (Foundation Medicine) announced the expansion of its
ongoing collaboration with Clovis Oncology, Inc. (Clovis) to
incorporate a coordinated regulatory strategy for the development
of a novel Premarket Approval (PMA) companion diagnostic test,
designed for use by physicians to identify patients most likely to
respond to rucaparib. "In addition to helping bring an important
new therapy to patients with ovarian cancer, this collaboration
marks a paradigm shift in the development of companion diagnostics.
The use of Foundation Medicine's platform is an important step in
the evolution of cancer care from a static, single-gene companion
diagnostic approach toward a universal companion diagnostic
standard," said Michael J. Pellini,
M.D., President and CEO of Foundation Medicine. "This agreement
complements Foundation Medicine's plans to develop an FDA-approved
companion diagnostic and supports our overall strategy to work with
the FDA to establish the appropriate regulatory framework for
novel, comprehensive genomic profiling platforms. We are very
pleased to continue our support of Clovis' highly differentiated
clinical development program and maintain our efforts with the
company to identify the ovarian cancer patients most likely to
benefit from rucaparib." The full analyst notes on Foundation
Medicine, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04092014/FMI/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review